PARP1 and renal cell carcinoma: Furthermore, because the use of poly (ADP-ribose) polymerase (PARP) inhibitors in RCC is not clinically indicated [2], it would be helpful to expand the usage of PARP inhibitors in certain RCC patients in whom the benefits would be promising.